Literature DB >> 22406601

Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Pandanaboyana Sanjay1, Rodrigo S de Figueiredo, Heather Leaver, Simon Ogston, Christoph Kulli, Francesco M Polignano, Iain S Tait.   

Abstract

CONTEXT: There is paucity of data on the prognostic value of pre-operative inflammatory response and post-operative lymph node ratio on patient survival after pancreatic-head resection for pancreatic ductal adenocarcinoma.
OBJECTIVES: To evaluate the role of the preoperative inflammatory response and postoperative pathology criteria to identify predictive and/or prognostic variables for pancreatic ductal adenocarcinoma.
DESIGN: All patients who underwent pancreaticoduodenectomy for pancreatic ductal adenocarcinoma between 2002 and 2008 were reviewed retrospectively. The following impacts on patient survival were assessed: i) preoperative serum CRP levels, white cell count, neutrophil count, neutrophil/lymphocyte ratio, lymphocyte count, platelet/lymphocyte ratio; and ii) post-operative pathology criteria including lymph node status and lymph node ratio.
RESULTS: Fifty-one patients underwent potentially curative resection for pancreatic ductal adenocarcinoma during the study period. An elevated preoperative CRP level (greater than 3 mg/L) was found to be a significant adverse prognostic factor (P=0.015) predicting a poor survival, whereas white cell count (P=0.278), neutrophil count (P=0.850), neutrophil/lymphocyte ratio (P=0.272), platelet/lymphocyte ratio (P=0.532) and lymphocyte count (P=0.721) were not significant prognosticators at univariate analysis. Presence of metastatic lymph nodes did not adversely affect survival (P=0.050), however a raised lymph node ratio predicted poor survival at univariate analysis (P<0.001). The preoperative serum CRP level retained significance at multivariate analysis (P=0.011), together with lymph node ratio (P<0.001) and tumour size (greater than 2 cm; P=0.008).
CONCLUSION: A pre-operative elevated serum CRP level and raised post-operative lymph node ratio represent significant independent prognostic factors that predict poor prognosis in patients undergoing curative resection for pancreatic ductal adenocarcinoma. There is potential for future neo-adjuvant and adjuvant treatment strategies in pancreatic cancer to be tailored based on preoperative and postoperative factors that predict a poor survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406601

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  22 in total

1.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

2.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Authors:  Sadaki Asari; Ippei Matsumoto; Hirochika Toyama; Makoto Shinzeki; Tadahiro Goto; Jun Ishida; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2015-06-25       Impact factor: 2.549

Review 3.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Authors:  Lewis Stevens; Samir Pathak; Quentin M Nunes; Sanjay Pandanaboyana; Christian Macutkiewicz; Neil Smart; Andrew M Smith
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

Review 4.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

5.  Diagnostic value of C-reactive protein and procalcitonin for postoperative pancreatic fistula following pancreatoduodenectomy: a systematic review and meta-analysis.

Authors:  Guoli Chen; Haizhao Yi; Jinguang Zhang
Journal:  Gland Surg       Date:  2021-12

6.  Does Preoperative Serum Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR) Predict Prognosis Following Radical Surgery for Pancreatic Adenocarcinomas? Results of a Retrospective Study.

Authors:  Vikas Gupta; Vikram Chaudhari; Shailesh V Shrikhande; Manish S Bhandare
Journal:  J Gastrointest Cancer       Date:  2021-08-18

7.  Prediagnostic Inflammation and Pancreatic Cancer Survival.

Authors:  Chen Yuan; Vicente Morales-Oyarvide; Natalia Khalaf; Kimberly Perez; Fred K Tabung; Gloria Y F Ho; Charles Kooperberg; Aladdin H Shadyab; Lihong Qi; Peter Kraft; Howard D Sesso; Edward L Giovannucci; JoAnn E Manson; Meir J Stampfer; Kimmie Ng; Charles S Fuchs; Brian M Wolpin; Ana Babic
Journal:  J Natl Cancer Inst       Date:  2021-09-04       Impact factor: 13.506

8.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Authors:  M Stotz; A Gerger; F Eisner; J Szkandera; H Loibner; A L Ress; P Kornprat; W AlZoughbi; W A Zoughbi; F S Seggewies; C Lackner; T Stojakovic; H Samonigg; G Hoefler; M Pichler
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 9.075

9.  Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.

Authors:  J Szkandera; M Stotz; G Absenger; T Stojakovic; H Samonigg; P Kornprat; R Schaberl-Moser; W Alzoughbi; C Lackner; A L Ress; F S Seggewies; A Gerger; G Hoefler; M Pichler
Journal:  Br J Cancer       Date:  2013-11-07       Impact factor: 9.075

10.  Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis.

Authors:  Hao Cheng; Feiwu Long; Mukesh Jaiswar; Lie Yang; Cun Wang; Zongguang Zhou
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.